Biocartis Group NV (8XB.SG)
| Previous close | 0.2595 |
| Open | 0.2595 |
| Bid | 0.2595 x 25000 |
| Ask | 0.3195 x 32200 |
| Day's range | 0.2595 - 0.2595 |
| 52-week range | 0.2565 - 0.5880 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 06 May 2024 - 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Globe NewswirePress release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of major shareholdings)
BIOCARTIS GROUP NV (Euronext Brussels: BCART) PRESS RELEASE - REGULATED INFORMATION - 10 January 2024, 23:00 CET Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of major shareholdings) 1. Summary of notice BIOCARTIS GROUP NV received a transparency notification on January 5, 2024, showing that JPMorgan Chase & Co., with registered office at c/o CT Corporation, 1209 Orange Street, Wilmington, DE19801, USA, following the acquisition
- Globe Newswire
Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of large shareholdings)
BIOCARTIS GROUP NV (Euronext Brussels: BCART) PRESS RELEASE - REGULATED INFORMATION - 10 January 2024, 23:00 CET Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of large shareholdings) 1. Summary of notice BIOCARTIS GROUP NV received a transparency notification on January 5, 2024, of which an amended version was received on January 8, 2024, showing that Invesco Ltd., with registered office at 1331, Spring Street NW, Suite 2500, Atl
Globe NewswirePress release Biocartis Holdings Inc.: Recapitalization completed and product portfolio expansion
PRESS RELEASE - 22 November 2023, 10:00 CET BIOCARTIS HOLDINGS INC. RECAPITALIZATION COMPLETED AND PRODUCT PORTFOLIO EXPANSION The recapitalization of Biocartis was completed last week, strengthening the balance sheet with a new investment of €40 million and a €132 million conversion of debt to equity.Product portfolio expansion with the launch of three breast cancer products: the Idylla™ PIK3CA-AKT1 Mutation Assay and, in collaboration with our partner APIS, the APIS Breast Cancer Subtyping Kit
